Ultragenyx Announces Approval of FAYUVI™ Gene Therapy, the First-Ever FDA-Approved Treatment for Sanfilippo Syndrome Type A
On Sept. 17, 2026, Ultragenyx Pharmaceutical announced that the U.S. Food and Drug Administration (FDA) granted standard full…